Curis To Present Updated Data From TakeAim Leukemia Study At The ASCO And EHA Conferences
Portfolio Pulse from Benzinga Newsdesk
Curis, Inc. announced an update on its TakeAim Leukemia study, expanding the AML dataset from 5 to 30 patients. The update will be presented at the ASCO and EHA conferences, including data for 25 new patients treated with emavusertib.
May 14, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Curis, Inc. announced significant progress in its TakeAim Leukemia study, expanding the dataset from 5 to 30 patients and presenting this data at the ASCO and EHA conferences. This update, focusing on the treatment with emavusertib, could positively influence investor perception and potentially impact the stock price.
The expansion of the dataset and the presentation at prestigious conferences like ASCO and EHA are likely to be viewed positively by investors. This could lead to increased investor confidence in Curis, Inc.'s pipeline and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100